Advances in Biomarker Research for Pancreatic Cancer

Author(s): Kruttika Bhat, Fengfei Wang, Qingyong Ma, Qinyu Li, Sanku Mallik, Tze-chen Hsieh, Erxi Wu

Journal Name: Current Pharmaceutical Design

Volume 18 , Issue 17 , 2012

Become EABM
Become Reviewer
Call for Editor


Pancreatic cancer (PC) is a leading cause of cancer related deaths in United States. The lack of early symptoms results in latestage detection and a high mortality rate. Currently, the only potentially curative approach for PC is surgical resection, which is often unsuccessful because the invasive and metastatic nature of the tumor masses makes their complete removal difficult. Consequently, patients suffer relapses from remaining cancer stem cells or drug resistance that eventually lead to death. To improve the survival rate, the early detection of PC is critical.

Current biomarker research in PC indicates that a serum carbohydrate antigen, CA 19-9, is the only available biomarker with approximately 90% specificity to PC. However, the efficacy of CA 19-9 for assessing prognosis and monitoring patients with PC remains contentious. Thus, advances in technology and the detection of new biomarkers with high specificity to PC are needed to reduce the mortality rate of pancreatic cancer.

Keywords: Pancreatic cancer, biomarker, tumor progression, risk factor, CA 19-9

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 23 April, 2012
Page: [2439 - 2451]
Pages: 13
DOI: 10.2174/13816128112092439
Price: $65

Article Metrics

PDF: 52